The first schizophrenia treatment to be taken just four times a year – with dosing measured in seasons, not days – is now available in the United States. The three-month dosing interval of INVEGA TRINZA (paliperidone palmitate) offers a new paradigm for treating patients with schizophrenia. With this newly available treatment option, healthcare providers can give patients greater independence by enabling them to focus less on taking their medication and more on other aspects of their treatment plan.
INVEGA TRINZA, an atypical antipsychotic injection, is administered just four times a year, providing the longest dosing interval available for people living with schizophrenia. Before starting INVEGA TRINZA, patients must be adequately treated with INVEGA SUSTENNA (one-month paliperidone palmitate) for at least four months, according to Johnson & Johnson.
Janssen Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) recently approved INVEGA TRINZA under Priority Review. This designation is for drugs that, if approved, would offer significant improvement in the treatment of serious conditions.